Venus Remedies receives Swiss market authorization for Gemcitabine

Venus Remedies receives Swiss market authorization for Gemcitabine

 Venus Remedies Limited has received its first marketing authorization in SWITZERLAND from Swiss drug authority (SWISSMEDIC) for Gemcitabine 200 mg & 1 g Injection through Venus Pharma GmbH. This market approval of critically important oncology drug Gemcitabine Injection will help Venus to strengthen its oncology portfolio. The company is planning to launch this product in early next quarter within this fiscal year to expand its presence in the oncology space. Venus Pharma GmbH the German subsidary will carry out complete analysis of the goods. The product will be launched in Switzerland market by Swiss Pharma GmbH with whom Venus has a marketing tie up.

Source: Venus Remedies (Link to full release)

About the author

Amitabh Arora

Amitabh Arora

Amitabh Arora has more than 18 years of experience promoting foreign direct investments (FDI), trade and economic relations between India and Switzerland, South Korea, United Kingdom and Canada. He is currently working as Director Key Accounts at the Greater Geneva Berne area (GGBa), the economic development agency of western Switzerland. GGBa offers a comprehensive range of services at no charge to foreign companies seeking to establish a presence in Switzerland. He is also the founder of FDITracker.com, tracking FDI developments worldwide. Amitabh has a Masters in International Business from the Indian Institute of Foreign Trade (IIFT) and a Bachelor of Business Studies (BBS) from College of Business Studies, India.

    Leave a Reply